Get the Stockscreener App
17.87
1.25%
0.22
Pre-market:
17.56
-0.31
-1.73%
Odyssey Therapeutics Inc stock is traded at $17.87, with a volume of 451.89K.
It is up +1.25% in the last 24 hours and up +1.42% over the past month.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
See More
Previous Close:
$17.65
Open:
$17.83
24h Volume:
451.89K
Relative Volume:
3.76
Market Cap:
$843.00M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-11.93
EPS:
-1.4981
Net Cash Flow:
-
1W Performance:
+4.56%
1M Performance:
+1.42%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$17.33
$18.25
1-Week Range:
$16.00
$18.38
52-Week Range:
$16.00
$18.60
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Name
Odyssey Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ODTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
17.87 | 832.62M | 0 | 0 | 0 | -1.4981 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Odyssey Therapeutics Inc Stock (ODTX) Latest News
FMR LLC's Strategic Acquisition of Odyssey Therapeutics Inc Shar - GuruFocus
IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace
Anthony W. Opipari Net Worth (2026) - GuruFocus
Aranicki Ksenija Pavletic Net Worth (2026) - GuruFocus
Todd Collin M Net Worth (2026) - GuruFocus
Natalie Dales Net Worth (2026) - GuruFocus
Gary D Glick Net Worth (2026) - GuruFocus
FMR LLC discloses 4.58M-share stake in Odyssey Therapeutics (ODTX) - Stock Titan
Odyssey Therapeutics (ODTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
ODTX Technical Analysis & ETF Price Forecast - Intellectia AI
Latest ODTX ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
ODTX Initiates Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
ODTX Initiates Coverage by JP Morgan -- Price Target Set at $26 - GuruFocus
ODTX Initiated Coverage by Cantor Fitzgerald -- Rated Overweight - GuruFocus
ODTX Initiates Coverage by Wedbush -- Price Target Announced at $30 - GuruFocus
Odyssey Therapeutics (ODTX) Rated Outperform with $30 Target - GuruFocus
ODTX Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
A Quick Look at Today's Ratings for Odyssey Therapeutics(ODTX.US), With a Forecast Between $16.96 to $40 - Moomoo
Wedbush Initiates Odyssey Therapeutics at Outperform With $30 Price Target - marketscreener.com
Oppenheimer initiates Odyssey Therapeutics stock with outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Odyssey Therapeutics stock with outperform rating - Investing.com
TD Cowen initiates Odyssey Therapeutics stock at Buy on drug pipeline - Investing.com
Cantor Fitzgerald Initiates Odyssey Therapeutics at Overweight - marketscreener.com
Oppenheimer Initiates Odyssey Therapeutics at Outperform With $40 Price Target - marketscreener.com
TD Cowen Initiates Odyssey Therapeutics at Buy - marketscreener.com
JPMorgan Initiates Odyssey Therapeutics at Overweight With $26 Price Target - marketscreener.com
JPMorgan initiates Odyssey Therapeutics stock rating at Overweight By Investing.com - Investing.com India
JPMorgan initiates Odyssey Therapeutics stock rating at Overweight - Investing.com
Odyssey Therapeutics (ODTX) Stock Analysis Report | Financials & Insights - Benzinga
Health stocks Odyssey, Mobia disappoint on first day of trading - MSN
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:17.500|Chg%:-0.24 - TradingKey
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ODTX Technical Analysis | Trend, Signals & Chart Patterns | ODYSSEY THERAPEUTICS INC (NASDAQ:ODTX) - ChartMill
Odyssey Therapeutics hits $900M valuation in Nasdaq debut, stock climbs 13% before diving lower - MSN
ODTX SEC FilingsODYSSEY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Simeon George Discloses Investment at Odyssey Therapeutics with 8.0% Stake - TradingView
SR One funds disclose 8% Odyssey Therapeutics (ODTX) stake after IPO - Stock Titan
TPG funds take 7.8% Odyssey Therapeutics (ODTX) stake via $25M share purchase - Stock Titan
Odyssey Therapeutics (ODTX) Stock Forecast and Price Target 2026 - MarketBeat
Odyssey Therapeutics (ODTX) Stock Chart and Price History 2026 - MarketBeat
Dimension Management Discloses Investment at Odyssey Therapeutics with 7.1% Stake - TradingView
Jeito II S.L.P. Discloses Investment in Odyssey Therapeutics with 7.8% Stake - TradingView
What is the current Price Target and Forecast for Odyssey Therapeutics, Inc. (ODTX) - Zacks Investment Research
Immunology drug developer Odyssey seeks US IPO again - MSN
Odyssey Therapeutics Inc Stock (ODTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Odyssey Therapeutics Inc Stock (ODTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dimension Capital II, L.P. | Director |
May 08 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
1,831,383 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Sale |
18.00 |
1,780 |
32,040 |
440,981 |
| LEIDEN JEFFREY M | Director |
May 08 '26 |
Buy |
20.00 |
5,000 |
100,000 |
270,198 |
| Haas Jason | Chief Financial Officer |
May 08 '26 |
Buy |
20.00 |
1,000 |
20,000 |
62,908 |
| Li Nan (LN) | Director |
May 11 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| Chu Shelley | Director |
May 11 '26 |
Buy |
18.00 |
11,111 |
199,998 |
11,111 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):